Anzeige
Mehr »
Login
Donnerstag, 04.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Übernahme-News! Relay Medical im Fokus der Anleger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M0GQ ISIN: ES0157261019 Ticker-Symbol: 41L 
Tradegate
03.03.21
12:46 Uhr
43,900 Euro
-1,100
-2,44 %
Branche
Pharma
Aktienmarkt
IBEX MEDIUM CAP
1-Jahres-Chart
LABORATORIOS FARMACEUTICOS ROVI SA Chart 1 Jahr
5-Tage-Chart
LABORATORIOS FARMACEUTICOS ROVI SA 5-Tage-Chart
RealtimeGeldBriefZeit
42,60043,40003.03.
42,70043,30003.03.

Aktuelle News zur LABORATORIOS FARMACEUTICOS ROVI Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
LABORATORIOS FARMACEUTICOS ROVI Aktie jetzt für 0€ handeln
DiLABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria, both in Europe and the United States.1
DiLABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria, both in Europe and the United States2
24.02.LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the presentation related to the 2020 financial results-
24.02.LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the press release related to the full year 2020 financial results-
11.01.LABORATORIOS FARMACEUTICOS ROVI, S.A.: Liquidity contract: transactions conducted in the fourth quarter of 20204
11.12.20Edison Investment Research Limited: Laboratorios Farmacéuticos ROVI (ROVI): All Good Things Come in Threes305LONDON, UK / ACCESSWIRE / December 11, 2020 / Laboratorios Farmacéuticos ROVI's (ROVI's) recent capital markets day (CMD) highlighted the strong positioning of its three key franchises. Combined unit...
► Artikel lesen
27.11.20LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the results of the PRISMA-3 study of the efficacy and safety of Doria in schizophrenic patients in the journal npj Schizophrenia10
24.11.20LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the presentation related to its strategy update because of its 2020 Capital Markets Day.7
19.11.20ROVI's Target Price To Rise By 6.5 €/shr To 36 €/shr After Moderna Announces Effectiveness Of Its Vaccine64
11.11.20Laboratorios Farmaceuticos ROVI - Momentum continues across key franchises228Reported 9M20 numbers highlight continual strength in sales across key franchises and ongoing margin expansion. ROVI reported operating revenue of €302.1m (+12%). Within the low molecular weight heparin...
► Artikel lesen
05.11.20LABORATORIOS FARMACEUTICOS ROVI, S.A.: The Company releases the presentation related to the first nine months 2020 financial results6
20.10.20UPDATE 1-Spain's Rovi plans to start manufacturing Moderna vaccine 'very soon'25
20.10.20Spain's Rovi to start manufacturing Moderna vaccine "very soon" if approved14
01.10.20LABORATORIOS FARMACEUTICOS ROVI, S.A.: Liquidity contract: transactions conducted in the third quarter of 20202
29.07.20Laboratorios Farmacéuticos ROVI - Top-line growth, significant margin expansion284Laboratorios Farmacéuticos ROVI reported H120 operating revenue of €191.1m (+8% y-o-y), driven by strong growth in heparins (+23% to €104.0m) and in toll manufacturing (+31% to €34.8m), which offset...
► Artikel lesen
18.05.20Laboratorios Farmacéuticos ROVI - COVID-19 stockpiling positive impact354Laboratorios Farmacéuticos ROVI (ROVI) reported Q120 operating revenue of €101.0m (+23% y-o-y), driven by strong growth both in the speciality pharmaceutical business (+24% to €88.2m) and in the toll...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1